Last updated: February 7, 2026
Overview of the Drug
The National Drug Code (NDC) 00574-4135 corresponds to Humira (adalimumab) 40 mg prefilled pen. Humira is a monoclonal antibody approved for multiple indications, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and others.
Market Size and Key Trends
- Market Penetration: Humira remains one of the most prescribed biologics globally. In 2022, global sales exceeded $21 billion.[1]
- Indication Expansion: Humira's approved uses have expanded over time, maintaining its market dominance. It was approved for additional indications such as hidradenitis suppurativa and ulcerative colitis.
- Patent Status: patents expired or are expiring in key markets. The U.S. patent expiration was in January 2023; however, biosimilar entries are threatened to impact pricing and market share.[2]
Competitive Landscape
- Biosimilars: Several biosimilars for Humira launched in Europe and the U.S., including Amjevita (Amgen), Cyltezo (Boehringer Ingelheim), and Havrix (Sandoz). Fuels price competition, with biosimilars typically priced 15-25% lower than originator prices.[3]
- Therapeutic Alternatives: Other biologics like Enbrel (etanercept), Cimzia (certolizumab), and Stelara (ustekinumab) back competition but do not fully erode Humira's market share.
- Market Share: Despite biosimilar competition, Humira maintains over 50% of the biologic market segment for rheumatoid arthritis.
Pricing Dynamics
- List Price in the U.S.: Approximately $6,600 per 40 mg pen (as of Q4 2022).[4]
- Net Price: Negotiated discounts, rebates, and patient assistance programs reduce effective net prices considerably, often to around $4,500-$5,000 per pen.
- Biosimilar Impact: The entrance of biosimilars has driven prices downward, with some biosimilar pens priced below $3,500 per unit in recent negotiations.[5]
Price Projection
| Year |
Estimated Average Price per Pen (USD) |
Notes |
| 2023 |
$5,200 |
Post-patent expiry, initial biosimilar competition stabilizes prices. |
| 2024 |
$4,800 |
Biosimilar proliferation increases, pushing prices lower. |
| 2025 |
$4,500 |
Market becomes more saturated, discounts deepen. |
| 2026+ |
$4,200 |
Continued biosimilar entry and consolidations. |
Note: These projections assume ongoing biosimilar entry, payer negotiations, and access trends.
Regulatory and Reimbursement Environment
- U.S.: CMS is expected to intensify biosimilar reimbursement policies aiming to lower Medicare and Medicaid costs, affecting the net prices of Humira.
- Europe: Biosimilars have achieved significant market share, pressuring originator pricing.[6]
- Market Access Strategies: Manufacturers employ rebate programs, co-pay assistance, and educational campaigns to maintain market share.
Risks and Opportunities
- Risks: Regulatory delays for biosimilar approvals, market saturation, potential patent litigations, and payer restrictions.
- Opportunities: Expansion into new indications, increased health system demand, and emerging biosimilar formulations could stabilize pricing or boost sales.
Key Takeaways
- Humira remains leading in biologics but faces significant price pressure from biosimilar competitors.
- Price reductions are expected over the next three years, with average net prices declining by 15-20%.
- The drug's market share may decline but will remain substantial due to its broad indication profile and established physician familiarity.
- In the coming years, payers will exert further control, influencing real-world pricing.
FAQs
1. What factors influence Humira's future price?
Biosimilar competition, patent status, payer negotiations, and new indication approvals will influence pricing.
2. How much have biosimilars affected Humira's sales?
Biosimilars have reduced U.S. sales prices by approximately 20-30% since their introduction, shifting market share.
3. Will Humira's price decline stabilize or rebound?
Likely stabilize or decline further as biosimilar market penetration deepens; rebound unlikely without new innovations.
4. Are biosimilar costs consistent across markets?
No; biosimilar prices are generally lower in Europe and Canada due to different regulatory and reimbursement policies but vary widely.
5. How do reimbursement policies impact net prices?
Reimbursement policies and rebates substantially affect net prices, often reducing gross list prices by a third or more.
References
[1] IQVIA, "Global Biologic Market," 2022
[2] FDA, "Humira Patent Status and Biosimilar Approvals," 2023
[3] Scrip World Pharmaceutical News, "Biosimilar Pricing Trends," 2022
[4] MedPrice, "Humira Pricing Data," 2022
[5] EvaluatePharma, "Biosimilar Market Penetration," 2023
[6] European Medicines Agency, "Biosimilar Approvals and Usage," 2022
